Overview

Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly

Status:
Unknown status

Trial end date:
2019-11-01

Target enrollment:

Participant gender:

Summary

A randomized controlled, open label, multicenter trial with 1000 patients aged 70 years and older, presenting with Non-ST-elevation acute coronary syndrome. Patients will be randomized to either clopidogrel or the novel P2Y12 inhibitor (ticagrelor or prasugrel). Patients will be followed for one year for outcomes such as bleeding episode requiring medical intervention and net clinical benefit (all cause mortality, non-fatal myocardial infarction, non-fatal stroke, PLATO major and minor bleeding).

Phase:

Phase 4

Details

Lead Sponsor:

St. Antonius Hospital

Collaborators:

Atrium Medical Center
Diakonessenhuis, Utrecht
Gelderse Vallei Hospital
Gelre Hospitals
Groene Hart Ziekenhuis
Isala
Leiden University Medical Center
Meander Medical Center
Medical Center Alkmaar
Medical Centre Leeuwarden
Rijnstate Hospital
UMC Utrecht

Treatments:

Clopidogrel
Prasugrel Hydrochloride
Ticagrelor
Ticlopidine